House of Delegates today passed the Endocrine Society's resolution to improve access to anti-obesity medications.

My years dedicated to patient care have provided a deep understanding of the profound impact obesity has on individuals' lives, extending far beyond the numbers on a scale.

The Endocrine Society today endorsed the introduction of the bipartisan Treat and Reduce Obesity Act (TROA) in the Senate.

The benefits consultant Mercer has said that 44% of U.S. companies with 500 or more employees covered obesity drugs last year. Medicare does pay for drugs like Wegovy for patients who have heart ...

whom Trump tapped to head the Centers for Medicare and Medicaid Services, has touted anti-obesity drugs on his talk show and on social media. “For those who want to lose a few pounds ...

As a physician assistant in Charlotte, I have witnessed firsthand the transformative impact of new obesity medications on ...

The National Council on Aging (NCOA), the national voice for every person's right to age well, applauds today's ...

Researchers found that injectable GLP-1 receptor agonists for obesity tended to yield smaller reductions in weight in ...

Despite axing a Biden-era proposal for government coverage of obesity drugs, health officials have signaled a potential path ...

The supply of GLP-1 drugs has been increasing, but they’re still expensive for most patients. Here are answers to some ...